GlassScriptPhysician profile
Vicente Lago
NPI 1619068095
$9,512.13
in general payments reported to CMS, 2019-2025
32 companies · $1,274 in 2025
The $1,274 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,252 · 2020: $1,057 · 2021: $1,400 · 2022: $1,565 · 2023: $1,313 · 2024: $1,651 · 2025: $1,274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,238.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,696.24 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,492.57 | 2019-2025 | Xifaxan, Trulance |
| Qol Medical, LLC | $1,435.29 | 2020-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $402.11 | 2019-2024 | Linzess |
| Madrigal Pharmaceuticals | $367.91 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $325.93 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $303.65 | 2022-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $283.46 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $273.60 | 2020-2023 | |
| Janssen Biotech, INC. | $239.83 | 2019-2025 | Stelara, Tremfya |
| Allergan, INC. | $203.33 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $175.58 | 2019-2022 | |
| Redhill Biopharma INC. | $173.31 | 2020-2021 | |
| Braintree Laboratories, INC. | $134.05 | 2019-2025 | Sutab, Suflave |
| Janssen Scientific Affairs, LLC | $122.83 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $122.49 | 2020-2022 | |
| Exact Sciences Corporation | $106.68 | 2023-2025 | Cologuard Collection Kit |
| Aimmune Therapeutics, INC. | $93.40 | 2024-2025 | Zenpep |
| Celgene Corporation | $86.49 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $73.39 | 2022-2024 | Dupixent |
| Celltrion USA INC. | $60.05 | 2024-2025 | Vegzelma |
| Lilly USA, LLC | $58.55 | 2024-2025 | Omvoh |
| Genzyme Corporation | $50.97 | 2022-2024 | |
| Gilead Sciences, INC. | $43.62 | 2019-2021 | |
| Organon LLC | $38.00 | 2021 | |
| Fresenius Kabi USA, LLC | $33.76 | 2023 | |
| Novo Nordisk INC | $28.01 | 2025 | Wegovy |
| Vivus LLC | $22.54 | 2022 | |
| Pharmacosmos Therapeutics INC. | $20.85 | 2025 | Monoferric |
| Concordia Pharmaceuticals INC. | $18.23 | 2019 | |
| Evoke Pharma, INC. | $13.97 | 2023 | Gimoti |
| Pentax of America, INC. | $11.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vicente Lago listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.